RT Journal Article
SR Electronic
T1 Determinants of SARS-CoV-2 anti-spike antibody levels following BNT162b2 vaccination: cross-sectional analysis of 6,000 SIREN study participants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.21.22274025
DO 10.1101/2022.04.21.22274025
A1 Otter, Ashley David
A1 D’Arcangelo, Silvia
A1 Whitaker, Heather
A1 Hewson, Jacqueline
A1 Foulkes, Sarah
A1 Atti, Ana
A1 Cole, Michelle
A1 Linley, Ezra
A1 Tonge, Simon
A1 Hettiarachchi, Nipunadi
A1 Sajedi, Noshin
A1 Calbraith, Davina
A1 Norman, Chris
A1 de Lacy, Elen
A1 Price, Lesley
A1 Stewart, Sally
A1 Cromey, Lisa
A1 Corrigan, Diane
A1 SIREN study group
A1 Rowe, Cathy
A1 Brown, Colin S
A1 Islam, Jasmin
A1 Semper, Amanda
A1 Hopkins, Susan
A1 Hall, Victoria
A1 Brooks, Tim
YR 2022
UL http://medrxiv.org/content/early/2022/04/21/2022.04.21.22274025.abstract
AB Background Understanding immunological responses to SARS-CoV-2 vaccinations is integral to the management of SARS-CoV-2. We aimed to investigate determinants of antibody response to the BNT162b2 vaccine.Methods A cross-sectional analysis of anti-spike binding antibodies in serum samples from healthcare workers after one or two doses. Post-vaccination interval was restricted to ≥21 days after dose 1, ≥14 days after dose 2. The primary outcome was anti-S titres with explanatory variables dose, previous infection, dosing interval, age, ethnicity, and comorbidities. Multivariable linear regression was also conducted.Results Participants (n=5,871) included 3,989 post-dose 1, 1,882 post-dose 2. In SARS-CoV-2 infection naïve, 99.65% seroconverted after dose 1 and >99.9% seroconverted after dose 2. Geometric mean anti-S titre in the naïve cohort was 75.48 Binding Antibody Units/ml after dose 1, 7,049 BAU/ml after dose 2. Anti-S titres were higher in those with previous infection (2,111 BAU/ml post-dose 1, 16,052 BAU/ml post-dose 2), and increased with time between infection and vaccination: 3 months 1,970 (1,506-2,579) vs 9 months; 13,759 (8,097-23,379). Longer dosing intervals increased antibody response post-dose 2: 11-fold higher with a longer interval (>10 weeks) than those with shorter intervals, across all age-groups. Younger participants had higher mean titres (>2.2-fold higher). Multivariable regression modelling corroborated the above associations, and also found higher titres associated with being female or from an ethnic minority but lower titres among immunocompromised participants.Conclusion The number of antigen exposures and timing between vaccinations plays a significant role in the magnitude of the post-vaccination antibody response, with implications for long-term protection and post-booster antibody responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study is funded by the Department for Health and Social Care and UKHSA (formerly PHE), with contributions from the governments of Northern Ireland, Scotland and Wales. Funding was also provided by The National Institute for Health Research (NIHR) as an Urgent Public Health Priority Study and through the Health Protection Research Units. The study was also awarded grant funding from the Medical Research Council (Grant title: Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was registered, number ISRCTN11041050, and received approval from the Berkshire Research Ethics Committee on 22 May 2020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnnotated code for this analysis is available at: (https://github.com/SIREN-study/SARS-CoV-2-Immunity). The metadata for this analysis will be available to researchers through the Health Data Research UK CO-CONNECT platform and available for secondary analysis. https://github.com/SIREN-study/SARS-CoV-2-Immunity